Tento dokument je výňatok z webového sídla EUR-Lex
Dokument 62018TN0347
Case T-347/18: Action brought on 1st of June 2018 — Laboratoire Pareva and Biotech3D v Commission
Case T-347/18: Action brought on 1st of June 2018 — Laboratoire Pareva and Biotech3D v Commission
Case T-347/18: Action brought on 1st of June 2018 — Laboratoire Pareva and Biotech3D v Commission
OJ C 285, 13.8.2018, s. 37 – 37
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
Case T-347/18: Action brought on 1st of June 2018 — Laboratoire Pareva and Biotech3D v Commission
Action brought on 1st of June 2018 — Laboratoire Pareva and Biotech3D v Commission
(Case T-347/18)
2018/C 285/53Language of the case: EnglishParties
Applicants: Laboratoire Pareva (Saint Martin de Crau, France) and Biotech3D Ltd & Co. KG (Gampern, Austria) (represented by: K. Van Maldegem and S. Englebert, lawyers)
Defendant: European Commission
Form of order sought
|
— |
declare the application admissible and well-founded; |
|
— |
annul the European Commission’s Implementing Regulation (EU) 2018/613 ( 1 ) of 20 April 2018 approving PHMB (1415; 4.7) as an existing active substance for use in biocidal products of product-types 2 and 4 under Regulation 528/2012 ( 2 ) (the ‘Contested Act’); and |
|
— |
order the defendant to pay the costs of these proceedings. |
Pleas in law and main arguments
In support of the action, the applicants rely on three pleas in law which are in essence identical or similar to those relied on in Case T-337/18, Laboratoire Pareva v Commission.
( 1 ) Commission Implementing Regulation (EU) 2018/613 of 20 April 2018 approving PHMB (1415; 4.7) as an existing active substance for use in biocidal products of product-types 2 and 4 (OJ 2018, L 102, p. 1)
( 2 ) Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products (OJ 2012, L 167, p. 1)